Atea Pharmaceuticals, Inc.
AVIR· Nasdaq
Released Mar 6, 2025, after the close
10-K filed Mar 6, 2025, 65 days after period end · 0000950170-25-034808
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $192.18M |
| Net Income | -$33.54M |
Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR
| -$39.16M |
| -$34.43M |
| $117.13M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.